The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
Phase I
9524: A Phase I Study of Pomalidomide Given at the Time of Lymphocyte Recovery Following Induction Timed Sequential Chemotherapy with Cytarabine, Daunorubicin and Etoposide (AcDVP16) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk MDS. Johns Hopkins University; Gojo, Ivana. (410) 328-2596
Phase II
9539: A Randomized, Prospective, Phase II Study to Determine the Efficacy of Bacillus Calmette-Guerin (BCG) Given in Combination with PANVAC(TM) Versus BCG Given Alone in Adults with High Grade Non-Muscle Invasive Bladder Cancer (NMIBC) Who Failed at Least 1 Induction Course of BCG. National Cancer Institute Urologic Oncology Branch; Agarwal, Piyush K. (301) 496-6353
ACNS1221: A Phase II Study for the Treatment of Non-Metastatic Nodular Desmoplastic Medulloblastoma in Children Less Than 4 Years of Age. Children’s Oncology Group; Lafay-Cousin, Lucie. (403) 955-2554
ACRIN-6702: A Multi-Center Study Evaluating the Utility of Diffusion Weighted Imaging for Detection and Diagnosis of Breast Cancer. American College of Radiology Imaging Network; Partridge, Savannah Corrina (206) 288-1306
E2212: A Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Adjuvant Everolimus Following the Resection of Metastatic Pancreatic Neuroendocrine Tumors to the Liver. Eastern Cooperative Oncology Group; Libutti, Steven Kenneth. (718) 920-4231
S1310: Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer. Southwest Oncology Group; Kim, Richard D. (813) 745-1277
Phase III
A091105: A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF). Cancer and Leukemia Group B; Gounder, Mrinal Murugesan. (646) 888-4167
Other Phases
AALL13B10-Q: Mechanisms of Action of Bortezomib in Early T-Precursor Acute Lymphoblastic Leukemia (ALL). Children’s Oncology Group; Horton, Terzah M. (832) 824-4269
AALL13B11-Q: Translocations and Their Widespread Impact on Gene Regulation. Children’s Oncology Group; Skok, Jane A. (212) 263-0504
AALL13B7-Q: Acute Lymphoblastic Leukemia Therapy By Targeting Cancer Stem Cells. Children’s Oncology Group; Schore, Reuven Joshua. (202) 476-2800
ANBL13B8-Q: The Genetic Basis of Neuroblastoma Tumorigenesis. Children’s Oncology Group; Maris, John M. (215) 590-5244
9510: Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients with Advanced Solid Tumors and Deleterious BRCA Mutations. National Cancer Institute Developmental Therapeutics Clinic; Kummar, Shivaani. (301) 435-5402
CITN-05: A Pilot Study of the Immunological Effects of Neo-Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma. Cancer Immunotherapy Trials Network; Odunsi, Kunle. (716) 845-8376
